Engle Martin & Associates, LLC Announces Acquisition of EIMC, LLC
17.4.2023 15:00:00 EEST | Business Wire | Press release
Engle Martin & Associates, LLC ("Engle Martin"), a market-leading independent loss adjusting and claims management provider, announced today that it has acquired EIMC, LLC (“EIMC”), a leading global provider of ocean marine, risk management, claims investigation, and subrogation services based in Jersey City, New Jersey and London, England.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230417005197/en/
Founded in 1968, EIMC serves clients across the entire marine global supply chain with 50+ years of expertise in providing the full continuum of assessments, risk mitigation, and claim resolution solutions within marine cargo, stock throughout, hull & machinery, and fine art & specie. EIMC operates in 15 office locations strategically positioned in the United States and the United Kingdom. The organization works with a broad group of clients in all major international insurance markets and is also the Lloyd’s Agent for multiple locations in the United States. Since its inception, EIMC has been recognized by major international insurers and numerous insurance associations as a premier provider of marine insurance risk management and claims services.
This acquisition expands Engle Martin’s global footprint and diversifies its service portfolio by providing clients with a full suite of ocean marine services. This acquisition also provides EIMC an extensive back-office infrastructure, innovative technology solutions, and growth opportunities for team members. EIMC has a remarkable history within the maritime community that has resulted in distinctive and long-lasting relationships with its clients and carrier partners. EIMC’s leadership team will remain in place and will maintain operational oversight of their portfolio.
When asked about the acquisition, Jay Campbell, Executive Vice President of Strategy & Organizational Growth of Engle Martin, said “We are excited to continue growing and investing in our business. The acquisition expands our service capabilities in the ocean marine & technical risk services arena with an organization that is well-aligned with our culture and approach to business. We will continue to provide our clients with the same service, quality, and capabilities they have come to expect from our team, with a complementary service that allows us to respond to our customers in a holistic manner.”
Tiina Ruhlandt, Managing Director of EIMC, said “We are delighted that Engle Martin appreciates the value of our organization; and we are confident and excited that our combined expertise will have a positive impact on our continued growth and success. We believe that this partnership is an excellent extension of Engle Martin’s long-term business strategy, and we are thrilled to have a partner who shares our principles and respects the culture which has driven our success.”
About Engle Martin
Engle Martin is a market-leading independent loss adjusting and claims management provider. Engle Martin has a comprehensive business philosophy: to provide the best insurance claim adjustment results in the industry, present the most talented claims professionals, foster an innovative and professional leadership team, and develop client-focused solutions. The firm provides a comprehensive line of service offerings including commercial property, casualty, specialty marine and transportation, appraisal/umpire, specialty audits, carrier outsourcing, and claims management services. For details about industries served and services offered by Engle Martin, visit EngleMartin.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230417005197/en/
Contact information
Dominique Enriquez
Marketing Director
+1 678.553.3872
denriquez@englemartin.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
